Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eprosartan

K J McClellan1, J A Balfour

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|May 20, 1998
PubMed
Summary
This summary is machine-generated.

Eprosartan effectively lowers blood pressure in patients with essential hypertension. This angiotensin II receptor antagonist demonstrates comparable efficacy to enalapril and a favorable safety profile with minimal drug interaction potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-grain scintillator screens for proton radiography.

The Review of scientific instruments·2024
Same author

Kondo quasiparticle dynamics observed by resonant inelastic x-ray scattering.

Nature communications·2022
Same author

Physics-informed machine learning for inorganic scintillator discovery.

The Journal of chemical physics·2018
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quantum critical fluctuations in the heavy fermion compound Ce(Ni0.935Pd0.065)₂Ge₂.

Journal of physics. Condensed matter : an Institute of Physics journal·2014
Same author

Anisotropic thermal conductivity in uranium dioxide.

Nature communications·2014
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Essential hypertension is a prevalent cardiovascular condition.
  • Angiotensin II receptor antagonists (ARAs) are a key therapeutic class.
  • Eprosartan is a nonpeptide ARA targeting the AT1 receptor subtype.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of eprosartan in patients with essential hypertension.
  • To compare eprosartan's effectiveness against placebo and enalapril.

Main Methods:

  • A 13-week study administering eprosartan (400-800 mg/day) to patients with mild to moderate hypertension.
  • A dose-titration study comparing eprosartan with enalapril in severe hypertension patients.

Main Results:

Related Experiment Videos

  • Eprosartan significantly reduced blood pressure compared to placebo.
  • Eprosartan demonstrated comparable efficacy to enalapril in severe hypertension.
  • The drug exhibited a tolerability profile similar to placebo, without causing cough.

Conclusions:

  • Eprosartan is an effective antihypertensive agent for essential hypertension.
  • Its favorable tolerability and low potential for drug interactions, due to lack of cytochrome P450 metabolism, make it a valuable therapeutic option.